Private Label Competition For Zegerid OTC Sets Sail With Perrigo Launch
This article was originally published in The Pink Sheet
Perrigo's omeprazole and sodium bicarbonate capsules indicated for the treatment of frequent heartburn will bear labeling that has been through several updates since the first PPI became available OTC in 2004.
You may also be interested in...
Less than a month after moving up from president to CEO, John Hendrickson tells analysts during the firm's first-quarter earnings briefing that Perrigo's private label OTC drug business remains strong, with the next launch ready to ship, but growing European branded consumer product sales is more of a long-term goal.
CDER approves sNDAs from Bayer for Zegerid OTC powder and private label manufacturer Dexcel Pharma for omeprazole delayed release tablets to add label warnings on drug-drug interactions for methotrexate and mycophenolate mofetil.
J&J names pharma vet to lead McNeil